Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease

NCT07704190 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Cardiorenal Metabolic Syndrome
Atherosclerotic Cardiovascular Disease
Chronic Kidney Disease
Coronary Artery Disease
Hypertension
Type 2 Diabetes Mellitus
Peripheral Arterial Disease
Carotid Artery Stenosis

Interventions

BIOLOGICAL: Secukinumab (75 mg)
OTHER: Standard Medical Therapy

Sponsor

Peking University Third Hospital